Antimicrobial proteins are effector molecules of the innate immune system and offer a fast response to invading microorganisms by exhibiting potent antimicrobial activity (19) . A major family of antimicrobial proteins in mammals comprises the beta-defensins. Beta-defensins are small (4 to 5 kDa), cationic proteins which exhibit a potent antimicrobial activity at microto nanomolar concentrations (12) . Human beta-defensin-3 (hBD-3) was originally isolated from lesional psoriatic skin extracts, and it is inducibly expressed in many epithelia, such as the skin, respiratory tract, and gut (4, 5, 12) . hBD-3 is characterized by its potent antibacterial activity against many bacteria, including multiresistant strains (5, 8, 15) . A BLAST search of the mouse protein database with the amino acid sequence of hBD-3 revealed highest identity (69%) to mouse beta-defensin-14 (mBD-14, Defb14) (Fig. 1) . The next-closest hit was mBD-3 (Defb3), with only 44% identity, followed by mBD-6, with only 38% identity. Interestingly, a BLAST search with the mature hBD-3 peptide revealed only one hit, mBD-14. This suggests that mBD-14 could be the mouse ortholog of hBD-3. However, no data exist regarding the biological function of mBD-14, and its potential role as an antimicrobial protein has not yet been evaluated. Therefore, we decided to recombinantly express mBD-14 in Escherichia coli and to analyze its antimicrobial activity.
We used the software program SignalP 3.0 (2) to determine the putative cleavage site in the mBD-14 amino acid sequence to generate the mature protein (Fig. 1) . The corresponding DNA encoding mBD-14 was amplified from mouse keratinocyte cDNA using the forward primer 5Ј-ATCCAGATCTGG GTACCGACGACGACGACAACTTCCTACCAAAAACCC TCC-3 and reverse primer 5Ј-ATTTGCGGGCGCCTACTTC TTCTTTCGGCAGC-3Ј. The resulting fragment was cloned into the expression vector pET32a(ϩ) (Novagen, Madison, WI) to generate a fusion protein containing an N-terminal His tag sequence allowing purification of the fusion protein by the use of a nickel affinity column. After expression in E. coli BL21(DE3)pLysS (Novagen), the fusion protein was purified using a nickel affinity column (Macherey-Nagel, Dueren, Germany), followed by preparative C 8 reversed-phase high-pressure liquid chromatography as described previously for the purification of human beta-defensin-3 (5) . The N-terminal part of the purified fusion protein was cleaved off by incubation for 1 h at 37°C with enterokinase (Invitrogen, Carlsbad, CA), and the resulting mature mBD-14 protein was purified by C 4 reversed-phase high-pressure liquid chromatography, similar to the method described previously (5) . Mass analysis using electrospray ionization mass spectrometry (QTOF-II hybrid mass spectrometer; Micromass, Manchester, United Kingdom) yielded a mass of 5,184.3 Da, which is 6 Da less than the theoretical mass calculated from the deduced amino acid sequence (5, 190.3 Da) , suggesting that the six cysteyl residues of mBD-14 are connected through three disulfide bridges.
To test the antimicrobial activity of mBD-14, a microdilution assay was used as previously described for RNase 8 (14) . Briefly, microorganisms were incubated at 37°C with different concentrations of mBD-14 in 10 mM sodium phosphate buffer containing 1% Trypticase soy broth. After 2 h, the antimicrobial activity of mBD-14 was analyzed by plating serial dilutions of the incubation mixture and determining the CFU the following day. Results are given either as the minimal bactericidal concentration (Ն99.9% killing) or as the concentration necessary to kill 90% of the microorganisms (90% lethal dose [LD 90 ]). mBD-14 exhibited a broad spectrum of potent, nanomolar antimicrobial activity against various microorganisms, including gram-positive and gram-negative bacteria and the yeast Candida albicans (Table 1) . mBD-14 was also able to efficiently kill methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis. Burkholderia cepacia was not susceptible to mBD-14, an observation also made for hBD-3 (15) . Together, these data show that mBD-14 exhibits antimicrobial activity which is comparable to the antimicrobial activity reported for hBD-3 (8, 15) . Moreover, the killing activities of mBD-14 and hBD-3 are influenced in a similar manner by higher salt concentrations and at a lower pH, thus further confirming their functional similarity (Table  2) . Interestingly, both peptides were able to kill S. aureus at 100 mM NaCl but completely lost their activity against E. coli at 100 mM NaCl (Table 2 ). In contrast, the susceptibility of E. coli to mBD-14 and hBD-3 was enhanced at pH 5.5, whereas the susceptibility of S. aureus was reduced. The high susceptibility of E. coli to mBD-14 and hBD-3 at pH 5.5 may be caused by synergistic killing effects, because we observed that a pH of 5.5 alone exhibited a slight killing effect against E. coli.
To obtain additional insight into the biological role of mBD-14, we analyzed its gene expression in various mouse tissues ( Fig. 2A) . Reverse transcription-PCR analyses revealed gene expression of mBD-14 in the tongue, thymus, tonsil, and kidney. All of these tissues have also been reported to express hBD-3 (5). As shown in Fig. 2A , mBD-14 mRNA was also expressed in skin and in primary keratinocytes, suggesting a role for mBD-14 in cutaneous defense. This is in concordance with several studies indicating that hBD-3 participates in skin innate immunity (5, 7, 16) . In addition, we found that gene expression of mBD-14 in primary mouse keratinocytes was induced by treatment of the cells with gamma interferon (IFN-␥) or transforming growth factor alpha (TGF-␣) (Fig.  2B ), which were also identified as stimuli for the induction of hBD-3 expression in human keratinocytes (4, 6, 11) . Further parallelisms in the gene regulation of mBD-14 and hBD-3 can be deduced from comparison of the promoter regions of these genes. It has been shown that the transcription factors NF-B, STAT-1, and AP-1 are involved in both TNF-␣/IFN-␥-and bacterium-mediated hBD-3 gene induction (1, 9) . Interestingly, analysis of the mBD-14 promoter region using the Genomatix software program revealed that the promoter region of mBD-14 also contains putative binding sites for NF-B, STAT-1, and AP-1 (not shown). In summary, this is the first report demonstrating that mBD-14 exhibits potent antimicrobial activity, with an antimicrobial spectrum similar to that reported for hBD-3. In addition, as seen for hBD-3, the expression of mBD-14 in keratinocytes is induced by IFN-␥ and TGF-␣. These results, together with the high sequence identity between mBD-14 and hBD-3, indicate that mBD-14 is the functional ortholog of hBD-3.
Mouse models are useful for studying the in vivo relevance of antimicrobial proteins. The knockout mouse for the human cathelicidin LL-37 ortholog CRAMP has been extensively used to study the role of cathelicidins in innate immunity (3, 10) . Another study showed that matrilysin-deficient mice lacked mature Paneth cell-derived cryptdins and were more susceptible to orally administered bacteria (18) . Therefore, studying mBD-14 with mouse models could help us to further understand the role of antimicrobial peptides such as hBD-3 in host defense.
During revision of the manuscript, two other studies reported the identification of mBD-14 as the mouse ortholog of hBD-3 (13, 17) . The work of Taylor et al. (17) reported that hBD-3 and mBD-14 exhibit similar potent antimicrobial activities against S. aureus and Pseudomonas aeruginosa which are independent of intramolecular disulfide bonds. Röhrl et al. (13) reported that mBD-14 is active against E. coli but not against S. aureus, a finding that contrasts with our findings. However, it should be noted that whereas we used the mature peptide for analysis of antimicrobial activity, Röhrl et al. used an mBD-14-immunoglobulin fusion protein of approximately 37 kDa. In addition, both reports showed that mBD-14 exhibits chemotactic activities similar to those of hBD-3. Taken together, both reports confirmed that mBD-14 is the functional ortholog of hBD-3. 
